title: Improvement of obesity and glucose tolerance by acetate in Type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
abstract: Acetate has been found to have an inhibitory effect on the activity of carbohydrate-responsive element-binding protein (ChREBP) in cultured hepatocytes, this being a transcription factor that regulates several genes required for the conversion of glucose to fatty acids in the liver. The aim of this study was to investigate whether an oral administration of acetate would contribute to reducing lypogenic genes and protecting against obesity. We orally injected 5.2 mg/kg BW of acetate to obesity-linked type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. The treatment with acetate showed a marked reduction in lipid accumulation in the adipose tissue, protection against accumulation of fat in the liver, and improved glucose tolerance. An analysis by Northern blotting revealed that the transcripts of several lipogenic genes in the liver of OLETF rats were decreased by the acetate treatment. On the basis of those results, it was indicated that acetate was a potential compound to improve obesity and obesity-linked type 2 diabetes.
authors.affiliation: Department of Nutritional Science, Faculty of Health and Welfare Science, Okayama Prefectural University, Okayama, Japan. yamashit@fhw.oka-pu.ac.jp
authors.forename: Hiromi
authors.initials: H
authors.lastname: Yamashita
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Fujisawa
authors.forename: Erina
authors.initials: E
authors.lastname: Ito
authors.forename: Seika
authors.initials: S
authors.lastname: Idei
authors.forename: Nobuyo
authors.initials: N
authors.lastname: Kawaguchi
authors.forename: Masumi
authors.initials: M
authors.lastname: Kimoto
authors.forename: Miki
authors.initials: M
authors.lastname: Hiemori
authors.forename: Hideaki
authors.initials: H
authors.lastname: Tsuji
mesh_terms: D000085:Acetates / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D005951:Glucose Tolerance Test; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000096:biosynthesis; D008297:Male; D008954:Models, Biological; D009765:Obesity / Q000097:blood / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D020334:Rats, Inbred OLETF; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000085:Acetates; D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; D008055:Lipids; D012333:RNA, Messenger; D014280:Triglycerides; D002784:Cholesterol